|
|
Blood, 1 July 2006, Vol. 108, No. 1, pp. 184-191.
Prepublished online as a Blood First Edition Paper on March 9, 2006; DOI 10.1182/blood-2005-11-4454.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
Vladan P. Cokic,
Bojana B. Beleslin-Cokic,
Melanija Tomic,
Stanko S. Stojilkovic,
Constance T. Noguchi, and
Alan N. Schechter
From the Institute of Medical Research, and the Institute of Endocrinology, Diabetes and Diseases of Metabolism, Belgrade, Serbia and Montenegro; the Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, and the Laboratory of Chemical Biology, National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD.
Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP levels in human erythroid cells. We show now that hydroxyurea increases endothelial-cell production of NO; this induction of NO in human umbilical vein endothelial cells (HUVECs) and human bone marrow endothelial cell line (TrHBMEC) is blocked by competitive inhibitors of NO synthase (NOS), such as NG-nitro-L-arginine-methyl ester (L-NAME) and NG-nitro-L-arginine. It is dependent on cAMP-dependent protein kinase (PKA) and protein kinase B (PKB/Akt) activity. We found that hydroxyurea dose- and time-dependently induced rapid and transient phosphorylation of eNOS at Ser1177 in a PKA-dependent manner; inhibitors of PKB/Akt could partially abrogate this effect. In addition, hydroxyurea induced cAMP and cGMP levels in a dose-dependent manner, as well as levels of intracellular calcium in HUVECs. These studies established an additional mechanism by which rapid and sustained effects of hydroxyurea may affect cellular NO levels and perhaps enhance the effect of NO in myeloproliferative diseases. (Blood. 2006;108:184-191)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
V. R. Gordeuk, A. Campbell, S. Rana, M. Nouraie, X. Niu, C. P. Minniti, C. Sable, D. Darbari, N. Dham, O. Onyekwere, et al.
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease
Blood,
November 19, 2009;
114(21):
4639 - 4644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Bonini, K. Stadler, S. d. O. Silva, J. Corbett, M. Dore, J. Petranka, D. C. Fernandes, L. Y. Tanaka, D. Duma, F. R. M. Laurindo, et al.
Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation
PNAS,
June 24, 2008;
105(25):
8569 - 8574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Yin, X. Wang, B. M. Konda, J. M. Ong, J. Hu, M. R. Sacapano, M. K. Ko, A. J. Espinoza, D. K. Irvin, Y. Shu, et al.
Increase in Brain Tumor Permeability in Glioma-Bearing Rats with Nitric Oxide Donors
Clin. Cancer Res.,
June 15, 2008;
14(12):
4002 - 4009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Canalli, C. F. Franco-Penteado, S. T.O. Saad, N. Conran, and F. F. Costa
Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation
Haematologica,
April 1, 2008;
93(4):
605 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. P. Cokic, S. A. Andric, S. S. Stojilkovic, C. T. Noguchi, and A. N. Schechter
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
Blood,
February 1, 2008;
111(3):
1117 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Morris
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Hematology,
January 1, 2008;
2008(1):
177 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
